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Introduction
Fatty acid amide hydrolase (FAAH, EC 3.5.1.99), an integral
membrane-bound serine hydrolase,[1–2] is the main catabolic
enzyme of the fatty acid ethanolamides (FAEs) such as ananda-
mide (AEA) and oleamide.[3] Other enzymes that contribute to
termination of endocannabinoid (EC) action are N-acylethanol-
amine acid amidase[4] and monoacylglycerol lipase (MAGL).[5]
FAEs, together with 2-arachidonoylglycerol, are the main EC
signaling lipids, which, by interacting with type-1 and type-2
cannabinoid receptors (CB1R and CB2R), exert biological activity
and modulate a variety of physiological processes including
pain, inflammation, appetite, motility, sleep, thermoregulation,
cognition, and emotional states.[6–7] The analgesic effects of
CB1R and CB2R have been known for centuries;
[8] however, as
with other CBRs agonists, they produce a spectrum of motor
and psychotropic side effects mediated by central CB1R. Ac-
cordingly, a valuable therapeutic alternative should elicit the
desirable effects of CBR activation, while avoiding the negative
effects of global CB1R stimulation, through indirect receptor
agonism obtained by inactivation of EC-metabolizing enzymes.
The relevance of FAAH in the safe management of pain is sup-
ported by evidence that faah knockout mice display high AEA
levels in the central nervous system (CNS) and show an analge-
sic phenotype in models of both inflammatory pain (induced
by carrageenan) and acute pain (induced by formalin),[9] to-
gether with a decrease in the inflammatory responses,[10] and
improved sleep and memory acquisition.[11–12] In fact, FAAH in-
The unique role of fatty acid amide hydrolase (FAAH) in termi-
nating endocannabinoid (EC) signaling supports its relevance
as a therapeutic target. Inhibition of EC metabolizing enzymes
elicits indirect agonism of cannabinoid receptors (CBRs) and
therapeutic efficacy devoid of psychotropic effects. Based on
our previous ligands, and aiming at the discovery of new selec-
tive FAAH inhibitors, we developed a series of 12 new com-
pounds characterized by functionalized tricyclic scaffolds. All
the developed compounds display negligible activity on mon-
oacylglycerol lipase (MAGL) and CBRs. The most potent FAAH
inhibitors of the newly developed series, 6-oxo-5,6-dihydro-4H-
benzo[f]pyrrolo[1,2-a][1,4]diazepin-9-yl-6-phenylhexylcarbamate
(5h) and 4-oxo-5,6-dihydro-4H-benzo[f]pyrrolo[1,2-a][1,4]diaze-
pin-9-yl-(6-phenylhexyl)carbamate (5 i) (nanomolar FAAH inhibi-
tors, the latter of which also shows micromolar affinity at the
CB1R), were selected for further studies. Results of cell-based
studies on a neuroblastoma cell line (IMR32) demonstrated 5h,
5 i, and our reference compound 3 ([3-(3-carbamoylpyrrol-1-yl)-
phenyl] N-(5-phenylpentyl)carbamate) to lack any cytotoxic
effect, while all three showed the ability to decrease oxidative
stress by reducing the expression of the redox-sensitive tran-
scription factor NF-kB. Encouraged by these data, these com-
pounds were studied in vivo and were dosed orally in a mouse
model of neuropathic pain. At 10 mgkg@1 all the compounds
were able to relieve the hypersensitivity induced by oxaliplatin.
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hibition by increasing the endogenous concentration of its
substrates, protracts and potentiates their beneficial (therapeu-
tic) effects, without eliciting the classical CB1R agonist side ef-
fects (hypomotility, hypothermia, and catalepsy).[13] In 2016, the
serious adverse effects observed in a phase I study with an irre-
versible FAAH inhibitor (BIA 10-2474) led to a temporary sus-
pension of the development of FAAH inhibitors. Shortly there-
after, a report from the US Food and Drug Administration
(FDA)[14] concluded that BIA 10-2474 has a peculiar toxicity pro-
file that does not extend to other FAAH inhibitors. In fact, an
in-depth reinvestigation uncovered a series of off-target pro-
teins for the same compound.[15]
Chronic pain is a major public health problem that has a tre-
mendous impact on the quality of life of the patients, produc-
ing a significant economic and social burden.[16] Neuropathic
pain (a severe, debilitating and persistent form of chronic pain
that may arise from dysfunctional or damaged peripheral
nerves, spinal cord, or brain[17]) is poorly treated by convention-
al therapeutics, which also exhibit a series of drawbacks and
side effects. All the above considerations suggest that the use
of FAAH inhibitors may provide a safe and efficient approach
for the treatment of painful syndromes including neuropa-
thies.[17]
The crystal structure of FAAH enabled in-depth knowledge
of the enzyme features and functioning useful for the develop-
ment of selective inhibitors. The catalytic triad (S241, S217, and
K142; human isoform numbering) is accessible through the
acyl-binding channel and the “membrane access channel”.[18] In
proximity to the nucleophilic S241 residue, the oxyanion hole
accommodates the carbonyl oxygen atom of amide or ester
substrates by establishing hydrogen bonds. The various FAAH
inhibitors developed so far can be clustered into two families:
irreversible (e.g. , carbamates 1a[19] and 1b,[20] Figure 1) and re-
versible inhibitors (e.g. , a-ketooxazole 2,[21] Figure 1). In this
context, we recently reported the development of different
classes of compounds as inhibitors of EC metabolic enzymes:
potent and selective FAAH[22–23] or MAGL[24] inhibitors and
dual FAAH/MAGL[25] inhibitors useful in different pathological
states.[26–27]
As a continuation of our efforts in the discovery of FAAH in-
hibitors, herein we describe the development of pyrrole-based
analogues inspired by our previously identified ligands. This
new series of compounds (5a–l, Figure 1 and Table 1) are
based on our structural template, lead compound 3, which
was modified in a classical medicinal chemistry approach in-
volving structural rigidification by bridging the phenylpyrrole
scaffold. In particular, three types of tricyclic systems were ex-
plored: 1) a 6-6-5 system, pyrrolo[1,2-a]quinoxaline (also in-
spired by the structure of previously developed FAAH/MAGL
inhibitors typified by 4[25]) ; 2) a 6-6-5 system, pyrrolo[1,2-a]qui-
noxalin-4(5H)-one substituted at C6 or C8; and 3) the 6-7-5 sys-
tems 4,5-dihydro-6H-benzo[f]pyrrolo[1,2-a][1,4]diazepin-6-one
and 5,6-dihydro-4H-benzo[f]pyrrolo[1,2-a][1,4]diazepin-4-one
heterocycles, substituted at C9. These systems were tethered
to a piperazinyl urea or a carbamate via phenylhexyl, undecyn-
yl, or (monofluoro)phenoxyethoxyethyl lateral chains (Figure 1
and Table 1). Below we discuss the synthesis, molecular model-
ing, in vitro and in vivo biological properties of these new
FAAH inhibitors.
Results and Discussion
Chemistry
The synthesis of compounds 5a–l is illustrated in Schemes 1–5.
Reaction of pyrroloquinoxalyl intermediate 6[28–31] (Scheme 1)
with alkyl isocyanates 7a–c afforded piperazine carboxamide-
based compounds 5a–c, whereas reaction with the alkyl bro-
mides afforded the alkyl piperazine-based derivatives 5d,e.[32]
For the synthesis of 5 f (Scheme 2) application of the Curtius
rearrangement protocol to acid 8 with tert-butanol provided
the protected aniline 9. After Boc group removal, amine 10
was converted into the 1-phenylpyrrole derivative 11 by Clau-
son–Kaas reaction. Reduction of the nitro functionality led to
amine 12, which by treatment with triphosgene, provided qui-
noxalinone 13. Treatment with boron tribromide afforded
Figure 1. References 1–4 and title compounds 5a–l.
Scheme 1. Reagents and conditions: a) R1NCO, TEA, dry THF, reflux, 11 h, 59–
62%; b) R2Br, TEA, MeCN, reflux, 14 h, 71–75%.
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Table 1. IC50 and percent displacement values on FAAH and MAGL, as well as CB1R and CB2R for compounds 5a–l and reference compound 3.
[a]
Compd Structure IC50 [nm] (Displacement [%])
FAAH MAGL CB1R CB2R
5a
>50 mm
(15.4)
NT NT NT
5b
>50 mm
(7.7)
NT NT NT
5c
>50 mm
(7.19)
NT NT NT
5d
>50 mm
(12.7)
NT NT NT
5e
>50 mm
(5.8)
NT NT NT
5 f 520 NT
>50 mm
(46.2)
>50 mm
(6.6)
5g 460 NT
>50 mm
(25.7)
>50 mm
(4.3)
5h 83.5
>50 mm
(0.7)
>50 mm
(25.3)
>50 mm
(19.3)
5 i 94.1
>50 mm
(23.7)
6730 24300
5 j 2825.3
>10 mm
(5.7)
>50 mm
(49.0)
>50 mm
(25.5)
5k 1672.3
>10 mm
(7.5)
>50 mm
(42.5)
>50 mm
(39.3)
5 l 2687.3
>10 mm
(6.8)
>50 mm
(46.0)
>50 mm
(37.4)
3[22] 0.60 NA NA NA
[a] Values are the means of three experiments (n=3), and all SDs not indicated are within 10%. Percent displacement at the maximum concentration
tested is reported in brackets if the IC50 value is >10 or 50 mm. Tests were performed as previously described
[25] with FAAH from rat brain (82.7% sequence
identity and 97.2% sequence similarity with hFAAH) or MAGL COS from cytosol with 30 and 20 min incubation time at 37 8C, respectively. NT: not tested.
NA: not active.
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phenol 14, which was treated with phenylhexylisocyanate 7b
to afford 5 f.
Nitration of the 3-hydroxyphenylacetamide 15 (Scheme 3)
led to 16. Sequential hydrolysis of the acetamido group, Clau-
son–Kaas reaction, and reduction of the nitro functionality pro-
vided aminophenol 17. Cyclization carried on with triphosgene
afforded derivative 18, later converted into the urethane 5g.
After esterification and nitro group reduction of the nitrocar-
boxylic acid 19 (Scheme 4) the resulting aniline was subjected
to Clauson–Kaas reaction to give intermediate 20. This 1-phe-
nylpyrrole was converted into the 2-cyanopyrrole derivative
21. Selective reduction of the nitrile by treatment with sodium
borohydride in the presence of cobalt(II) chloride led to spon-
taneous cyclization to the pyrrolobenzo[1,4]diazepinone deriv-
ative 22. Cleavage of the methyl ether functionality followed
by treatment with phenylhexylisocyanate provided 5h.
For the preparation of compounds 5 i–l (Scheme 5) aryl fluo-
ride 23 was submitted to aromatic nucleophilic substitution
with methyl 1H-pyrrole-2-carboxylate in the presence of
cesium carbonate. The resulting 1-phenylpyrrole 24 was re-
duced, cyclized, and treated with boron tribromide, thus pro-
viding the pyrrolobenzo[1,4]diazepinone intermediate 25. Re-
action with isocyanates 7b or 26a–c[22] led to compounds 5 i–l.
Structure–activity relationship and molecular modeling
studies
The inhibitory potencies of compounds 5a–l for FAAH are
listed in Table 1. Selectivity toward MAGL, CB1R, and CB2R was
evaluated for the most promising compounds. The new com-
pounds showed an excellent selectivity profile for FAAH over
MAGL, CB1R, and CB2R, with only 5 i revealing single-digit mi-
cromolar affinity at CB1R and two-digit micromolar affinity at
CB2R. These data confirmed that the presence of an “activated”
electrophilic center (such as ureido or carbamoyl moieties) is a
crucial requirement for FAAH inhibition potency. In fact, com-
pounds 5a–e, where the electrophilic center is absent (5d,e)
Scheme 2. Reagents and conditions: a) tBuOH, DPPA, TEA, reflux, 15 h, 78%;
b) TFA, 0 8C, 1.5 h, 99%; c) 2,5-dimethoxytetrahydrofuran, AcOH, H2O, 100 8C,
15 min, 97%; d) Fe8, CaCl2, EtOH 75%, 80 8C, 2 h, 87%; e) CO(OCCl3)2, tolu-
ene, 120 8C, 2 h, 52%; f) BBr3, CH2Cl2, @78!25 8C, 12 h, 11%; g) 7b, TEA,
THF, 25 8C, 16 h, 30%.
Scheme 3. Reagents and conditions: a) HNO3, AcOH, Ac2O, 25 8C, 8 h, 98%;
b) 12n HCl, 130 8C, 5 h, 95%; c) 5n HCl, 2,5-dimethoxytetrahydrofuran, 1,4-
dioxane, 110 8C, 20 min, 70%; d) SnCl2·2H2O, EtOAc, 25 8C, 2 h, 85%;
e) CO(OCCl3)2, toluene, 120 8C, 2 h, 36%; f) 7b, TEA, THF, 25 8C, 16 h, 10%.
Scheme 4. Reagents and conditions: a) SOCl2, MeOH, 25 8C, 10 h;
b) SnCl2·2H2O, EtOAc, 25 8C, 2 h; c) 5n HCl, 2,5-dimethoxytetrahydrofuran,
1,4-dioxane, 110 8C, 5 min, 87% (over three steps) ; d) (COCl)2, NH2OH·HCl,
pyridine, DMF, 1,2-DCE, 0!120 8C, 10 h, 47%; e) NaBH4, CoCl2, MeOH, 25 8C,
30 min, 64%; f) BBr3, CH2Cl2, @78!25 8C, 12 h, 50%; g) 7b, TEA, THF, 25 8C,
16 h, 60%.
Scheme 5. Reagents and conditions: a) Methyl 1H-pyrrole-2-carboxylate,
Cs2CO3, dry DMF, 50 8C, 12 h, 30%; b) NaBH4, CoCl2, MeOH, 25 8C, 30 min,
71%; c) BBr3, dry CH2Cl2, @78!25 8C, 12 h, 50%; d) TEA, dry THF, 25 8C, 12 h,
43–55%.
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or where a urea group is present between the two aliphatic
amines (5b,c) were found to be inactive. If the urea involved
an aniline (5a) as the carbamoylating moiety, enzyme inhibi-
tion was still poor, although slightly higher than that of the
other urea-containing analogues of the series. In line with our
previous results, the insertion of a carbamate in the developed
molecules allowed us to identify a series of selective FAAH in-
hibitors (5 f–l) characterized by the presence of different scaf-
folds supporting the phenol moiety. The influence of polyether
lateral chains (as the enzyme carbamoylating entities) was ex-
plored for the most promising and synthetically accessible
scaffolds, which modulated FAAH inhibitory properties (5 j–l vs.
5 i).
To better understand the structure–activity relationships
(SARs) of the developed compounds, we performed molecular
docking studies to assess the interactions of the inhibitors with
FAAH at the atomic level. We performed an induced-fit dock-
ing (IFD) calculation as reported[33–35] to identify the main con-
tacts governing the behavior of our compounds with the
enzyme. The data were compared with those obtained by ap-
plying the same protocol to our previously described lead 3
(see the Supporting Information (SI) and Figure S1). In particu-
lar, 5h, one of the most potent compounds of this series, inter-
acts with the FAAH active site by polar and hydrophobic con-
tacts (Figure 2A,B). Polar contacts were established by the
lactam moiety and the backbones of V270 and C269. In line
with the potency of FAAH inhibition of 5h (IC50=83.5 nm,
Table 1) the electrophilic moiety is properly placed in front of
the catalytic serine residues (S217 and S241) which can estab-
lish hydrogen bonds with the carbamate phenate oxygen. The
orientation of the carbon of the carbamate portion and its dis-
tance from the catalytic S241 residue (<3 a) are in agreement
with a potential nucleophilic attack. The carbonyl group can
establish two hydrogen bonds with I238 and G239. Further-
more, the phenylhexyl lateral chain could be located in a hy-
drophobic sub-pocket lined by F192, F381, and F432, produc-
ing a double p–p stacking with F192 and F432. Compound 5 i
displayed similar interactions besides a correct orientation
toward S241 (p–p stacking with F381 and F432, hydrogen
bonds with C269 and V270, and interaction with the catalytic
S241; Figure 3A,B).
In compounds 5 j–l, the introduction of a polyether tether,
for replacing the hexyl chain of 5 i, caused a marked decrease
in FAAH inhibition. The docking outputs for 5 j–l clearly con-
firm the lack of potency (SI Figures S2A,B, S3A,B, S4A,B). The
polyether chain is diverted from accommodation in the hydro-
phobic sub-pocket of the enzyme (see superposition of 5 i and
5 j, Figure 3C) and prevents the carbamate from establishing
an interaction with the catalytic serine residue S241, while still
being able to establish two hydrogen bonds (with I238 and
G239 for 5 j and with S193 and G239 for 5 l and 5k).
In compound 5g the restricted 6-6-5 tricyclic system produ-
ces a binding mode quite different from that found for the 6-
7-5 system of 5h. The tricyclic system can only form a hydro-
gen bond with the backbone of C269, and in line with the
three-digit nanomolar potency of 5g (Table 1), it lacks a suita-
ble distance for interaction with S241. The different accommo-
dation of the more planar and bulkier tricyclic system prevents
projection of the aliphatic tail into the hydrophobic sub-
pocket (SI Figure S5A,B). The superposition of the IFD poses of
5h and 5g clearly illustrates the described differences (SI Fig-
ure S5C).
The same is true for compound 5 f (SI Figure S6A,B). In par-
ticular, the tricyclic moiety establishes only one polar contact
with T236. The carbamate group interacts with S217 and S241
by two hydrogen bonds, and the phenylhexyl tail forms a
double p–p stacking interaction with F192 and F381.
Cytotoxicity determination and potential antioxidant evalu-
ation for 3, 5h, and 5 i
Oxidative stress (OS) plays a crucial role in neuropathic pain,[36]
and our research group provided evidence that it plays a cru-
cial role in oxaliplatin-induced neuropathy.[37] On these bases,
we decided to interrogate the ability of the most potent FAAH
inhibitors of this series to decrease OS. Accordingly, the effica-
cy of compounds 5h and 5 i, in comparison with our lead 3,
was measured in a cellular acute model of OS induced by hy-
Figure 2. A) IFD pose and B) ligand interaction diagram of compound 5h (cyan sticks) in the FAAH enzyme (PDB ID: 3PPM in orange cartoon). The catalytic
triad of the enzyme is represented by sticks, while the key residues of the FAAH binding site are represented by lines. Hydrogen bonds are represented by
black dotted lines. Images were generated with PyMOL and Maestro (Maestro version 9.3, Schrçdinger LLC, New York, NY, 2012).
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drogen peroxide. By applying our previously described
model,[38] a preliminary test was performed to assess the ef-
fects of the tested compounds in the morphology of IMR32
cells. As outlined in Figure S7 of the SI, after treating the cells
for 24 h with increasing concentrations (between 0.1 and
50 mm) of 3, 5h, and 5 i, no changes were observed in cellular
morphology.
We then tested the cytotoxicity profile in the same cell line
by measuring the release of lactate dehydrogenase (LDH) in
the media, as measured by enzymatic assay (see the SI for de-
tails). As positive control (LDH amount corresponding to 100%
cell death) IMR32 cells were treated with 1% Triton X-100, ac-
cording to the manufacturer’s instructions (Roche, Mannheim,
Germany). Notably, no significant cytotoxic effect was observed
for all the tested compounds at concentrations ranging from
0.1 to 50 mm (SI, Figure S8).
These results with 3, 5h, and 5 i prompted us to evaluate
their potential anti-inflammatory and neuroprotective proper-
ties after treating the cells with pro-inflammatory substances.
To find the most appropriate model for probing anti-inflamma-
tory potential of our molecules in the IMR32 cell line we tested
several pro-inflammatory mediators. We first evaluated the ac-
tivation of NF-kB by measuring the translocation of its cyto-
plasmic subunit p65 to the nucleus. Accordingly, we treated
the cells with lipopolysaccharide (LPS; 100 mgmL@1 and
200 mgmL@1) for 30, 60, and 90 min. The 100 mg treatment
after 30 min was the most effective, in which we could clearly
observe the nuclear translocation of p65 protein (see SI Fig-
ure S9: the increment of the LPS bar with respect to the con-
trol bar). Thus, according to our protocol, we pre-treated the
cells with compounds 3, 5h, and 5 i for 24 h and subsequently
with 100 mgmL@1 LPS for 30 min. As shown in SI Figure S9, the
pre-treatment was able to decrease p65 translocation with re-
spect to the cells treated with LPS alone. Notably, while 5 i ex-
erted its higher anti-inflammatory action at 1 mm, compound
5h exerted an anti-inflammatory effect inversely proportional
to the dose.
In vivo efficacy: effect of acute administration of com-
pounds 3, 5h, and 5 i on oxaliplatin-induced neuropathic
pain
We evaluated the effect of compounds 3, 5h, and 5 i in a
mouse model of neuropathic pain, the chemotherapy-depen-
dent neuropathy induced by oxaliplatin.[39–40] The repeated ad-
ministration of the neurotoxic anticancer agent (2.4 mgkg@1,
i.p.) evoked an allodynia-like behavior measurable as increased
sensitivity to a non-noxious cold stimulus (cold plate test). On
day 14, the licking latency decreased to 10.7:0.9 s in compari-
son (P<0.01) to control mice (20.1:0.8 s) treated with vehicle
(Figure 4). FAAH inhibitors were tested in oxaliplatin-treated
animals on day 14, and the pain relieving effects were evaluat-
ed over time after a single orally administered dose of the test
compounds. We initially established that our potent and selec-
tive FAAH inhibitor 3 was able to dose-dependently increase
the pain threshold at 3 and 10 mgkg@1, peaking 30 min after
Figure 3. A) IFD pose and B) ligand interaction diagram of compound 5 i (yellow sticks) in the FAAH enzyme (PDB ID: 3PPM in orange cartoon). C) Superposi-
tion between IFD poses of 5 i (yellow sticks) and 5 j (blue sticks). The catalytic triad of the enzyme is represented by sticks, while the key residues of the FAAH
binding site are represented by lines. Hydrogen bonds are represented by dotted lines. Images were generated by PyMOL and Maestro (Maestro version 9.3,
Schrçdinger LLC, New York, NY, 2012).
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treatment. Based on this, we tested the analogues 5h and 5 i
(in a dose range of 3–30 mgkg@1 p.o.). As shown in Figure 4,
both compounds induced a significant relief of oxaliplatin-in-
duced neuropathic pain starting from 3 mgkg@1. Higher effects
were obtained using 5h and 5 i, administered at doses of 10
and 30 mgkg@1. These dosages were equally effective between
15 and 30 min after administration. Compound 5h was signifi-
cantly effective up to 45 min (Figure 4).
Conclusions
FAAH significantly contributes to the termination of EC signal-
ing and is a relevant therapeutic target. By inhibition of the
EC-metabolizing enzymes, one can attain indirect agonism at
CBRs and therapeutic efficacy devoid of psychotropic effects.
Aimed at the discovery of new selective FAAH inhibitors,
herein we have described the development and SAR analysis
of a series of new analogues (5a–l) bearing functionalized tri-
cyclic scaffolds and structurally inspired by our previous li-
gands 3 and 4. The developed compounds showed an excel-
lent selectivity profile for FAAH over MAGL, CB1R, and CB2R,
with 5 i showing some (micromolar) affinity at CBRs. The most
potent FAAH inhibitors of the series 5h and 5 i were used for
further studies. In assays with a neuroblastoma cell line
(IMR32) 5h, 5 i, and our reference compound 3 demonstrated
an absence of cytotoxic effects and the ability to reduce oxida-
tive stress by decreasing the expression of the redox-sensitive
transcription factor NF-kB. The efficacy of the same com-
pounds was also assessed in vivo in a rodent model of neuro-
pathic pain. After oral administration at 10 mgkg@1 all three
compounds were able to relieve the hypersensitivity induced
by oxaliplatin.
Experimental Section
Chemistry
Unless otherwise specified, materials were purchased from com-
mercial suppliers and used without further purification. Reaction
progress was monitored by TLC using silica gel 60 F254 (0.040–
0.063 mm) with detection by UV. Silica gel 60 (0.040–0.063 mm)
was used for column chromatography. 1H and 13C NMR spectra
were recorded on a Varian 300 MHz spectrometer or a Bruker
400 MHz spectrometer by using the residual signal of the deuterat-
ed solvent as internal standard. Splitting patterns are described as
singlet (s), doublet (d), triplet (t), quartet (q), and broad (br) ; chemi-
cal shift values (d) are given in ppm and coupling constants (J) in
Hertz (Hz). Microwave reactions were performed with a CEM Dis-
covery apparatus. ESI-MS spectra were performed with an Agilent
1100 Series LC/MSD spectrometer. High-resolution (HR) ESI-MS data
were collected on a Thermo Finningan LCQ Deca XP Max ion-trap
mass spectrometer equipped with Xcalibur software, operating in
positive ion mode. The yields refer to purified products and are
not optimized. All moisture-sensitive reactions were performed
under an argon atmosphere using oven-dried glassware and anhy-
drous solvents. Final compounds were analyzed by combustion
analysis (C,H,N) to confirm purity >95%.
N-Phenyl-4-(pyrrolo[1,2-a]quinoxalin-4-yl)piperazine-1-carboxa-
mide (5a): Compound 6 (60 mg, 0.24 mmol) was dissolved in dry
THF (2.0 mL) and TEA (33 mL, 0.24 mmol) was added. Then phenyl
isocyanate (7a) (52 mL, 0.47 mmol) was added dropwise and the re-
action mixture was heated at reflux for 12 h. After reaction comple-
tion volatiles were removed in vacuo and the residue was purified.
Column chromatography on silica gel (n-hexane/EtOAc 2:1) provid-
Figure 4. Pain relieving effect of compounds 3, 5h, and 5 i. Mice were treat-
ed with oxaliplatin (2.4 mgkg@1 i.p. daily for five consecutive days every
week for two weeks) to induce a painful neuropathy. Tested compounds
were administered p.o. on day 14, and control animals were treated with ve-
hicles. Pain threshold was evaluated measuring the licking latency to a cold
non-noxious stimulus (cold plate test). Each value represents the mean
:SEM of 12 mice performed in two different experimental sets. ~P<0.05
and ~~P<0.01 with respect to the value before treatment.
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ed pure title compound (62% yield) as a pale-yellow solid. 1H NMR
(300 MHz, CDCl3): d=3.74 (m, 4H), 3.91 (m, 4H), 6.45 (br s, 1H),
6.79 (m, 2H), 7.06 (m, 2H), 7.26–7.41 (m, 5H), 7.67–7.76 (m, 2H),
7.85 ppm (m, 1H); 13C NMR (75 MHz, CDCl3): d=43.7, 47.5, 106.7,
112.6, 113.3, 114.6, 120.0 (2C), 123.3 (2C), 124.3, 125.2, 125.8, 127.5,
128.9 (2C), 152.3, 155.0 ppm; ESI-MS m/z 372 [M+H]+ (100), 394
[M+Na]+ ; Elemental analysis calcd (%) for C22H21N5O: C 71.14, H
5.70, N 18.85, found: C 71.08, H 5.93, N1 8.70.
N-(6-Phenylhexyl)-4-(pyrrolo[1,2-a]quinoxalin-4-yl)piperazine-1-
carboxamide (5b): The title compound was prepared according to
the procedure previously described for 5a starting from 6 (100 mg,
0.40 mmol), TEA (56 mL, 0.40 mmol) and 6-phenyl-1-hexylisocyanate
(7b) (161 mg, 0.79 mmol). Column chromatography on silica gel
(n-hexane/EtOAc 1:1) provided pure title compound (59% yield) as
a pale-yellow amorphous solid. 1H NMR (300 MHz, CDCl3): d=1.28–
1.67 (m, 8H), 2.62 (t, J=7.8 Hz, 2H), 3.26 (m, 2H), 3.59 (m, 4H),
3.84 (m, 4H), 4.64 (br t, 1H), 6.77 (m, 2H), 7.15–7.36 (m, 7H), 7.68
(m, 2H), 7.82 ppm (m, 1H); ESI-MS m/z 456 [M+H]+ , (100) 478
[M+Na]+ ; Elemental analysis calcd (%) for C28H33N5O: C 73.82, H
7.30, N 15.37, found: C 73.75, H 7.51, N 15.71.
N-(Undec-10-yn-1-yl)-4-(pyrrolo[1,2-a]quinoxalin-4-yl)piperazine-
1-carboxamide (5c): The title compound was prepared according
to the procedure described for 5a starting from 6 (72 mg
0.29 mmol), TEA (40 mL, 0.29 mmol) and undec-10-yn-1-yl isocya-
nate (7c) (110 mg, 0.57 mmol). Column chromatography on silica
gel (n-hexane/EtOAc 2:1) provided pure title compound (60%
yield) as a pale-yellow amorphous solid. 1H NMR (300 MHz, CDCl3):
d=1.23–1.54 (m, 14H), 1.94 (m, 1H), 2.18 (m, 2H), 3.26 (m, 2H),
3.60 (m, 4H), 3.84 (m, 4H), 4.53 (br t, 1H), 6.78 (m, 2H), 7.26–7.32
(m, 2H), 7.64–7.74 (m, 2H), 7.83 ppm (s, 1H); ESI-MS m/z 446 [M+
H]+ , (100) 468 [M+Na]+ ; Elemental analysis calcd (%) for
C27H35N5O: C 72.78, H 7.92, N 15.72, found: C 72.73, H 8.14, N
16.03.
4-(4-(6-Phenylhexyl)piperazin-1-yl)pyrrolo[1,2-a]quinoxaline
(5d): 6-Phenylhexylbromide (96 mg, 0.40 mmol) was dissolved in
MeCN (HPLC grade, 4.0 mL) and the solution was heated at reflux.
Then, compound 6 (100 mg, 0.40 mmol) was added, followed by
TEA (61 mL, 0.44 mmol). The reaction mixture was heated at reflux
for 12 h and the volatiles were evaporated in vacuo. Column chro-
matography on silica gel (n-hexane/EtOAc 2:1) provided pure title
compound (75% yield) as a pale-yellow oil. 1H NMR (300 MHz,
CDCl3): d=1.39–1.69 (m, 8H), 2.42 (m, 2H), 2.64 (m, 6H), 3.85 (m,
4H), 6.78 (m, 2H), 7.19–7.30 (m, 7H), 7.72 (m, 2H), 7.81 ppm (m,
1H); 13C NMR (75 MHz, CDCl3): d=22.8, 23.5, 25.3, 25.3, 27.5, 32.0,
44.0 (2), 49.4 (2), 54.9, 102.8, 108.4, 109.3, 110.4, 116.3, 119.9, 121.2,
121.6, 121.8, 123.5, 124.3 (2C), 124.4 (2C), 132.3, 138.8, 148.6 ppm;
ESI-MS m/z 413 [M+H]+ ; Elemental analysis calcd (%) for C27H32N4 :
C 78.60, H 7.82, N 13.58, found: C 78.87, H 7.68, N 13.35.
4-(4-(Undec-10-yn-1-yl)piperazin-1-yl)pyrrolo[1,2-a]quinoxaline
(5e): The title compound was prepared according to the proce-
dure described for 5d starting from 6 (55 mg, 0.22 mmol), undec-
10-yn-1-yl bromide (50 mg, 0.22 mmol) and TEA (33 mL,
0.24 mmol). Column chromatography on silica gel (n-hexane/EtOAc
2:1) provided pure title compound (71% yield) as a pale-yellow oil.
1H NMR (300 MHz, CDCl3): d=1.26–1.56 (m, 14H), 1.94 (m, 1H),
2.20 (m, 2H), 2.41 (m, 2H), 2.64 (m, 4H), 3.84 (m, 4H), 6.76 (m, 2H),
7.22–7.35 (m, 2H), 7.67 (m, 2H), 7.81 ppm (m, 1H); ESI-MS m/z 403
[M+H]+ ; Elemental analysis calcd (%) for C26H34N4 : C 77.57, H 8.51,
N 13.92, found C 77.73, H 8.38, N 14.09.
tert-Butyl 3-methoxy-2-nitrophenylcarbamate (9): To a solution
of 3-methoxy-2-nitrobenzoic acid (8) (1 g, 5.08 mmol) in 20.0 mL of
tert-butanol were added diphenylphosphoryl azide (1.15 mL,
5.36 mmol) and TEA (0.75 mL, 5.42 mmol). The reaction mixture
was heated at reflux for 15 h, then cooled to 25 8C and solvents
were removed by rotary evaporation. Residue was taken up with
EtOAc and washed with a saturated aqueous solution of NH4Cl,
water, a saturated solution of NaHCO3 and brine. The organic layer
was dried over anhydrous Na2SO4, filtered and concentrated afford-
ing the title compound (78% yield). 1H NMR (300 MHz, CDCl3): d=
1.38 (s, 9H), 3.83 (s, 3H), 6.68 (dd, J=7.5, 1.5 Hz, 1H), 7.71 (t, J=
7.5 Hz, 1H), 8.09 (dd, J=7.5, 1.5 Hz, 1H), 9.15 ppm (br s, 1H); ESI-
MS m/z 291 [M+Na]+ (100).
3-Methoxy-2-nitroaniline (10): Compound 9 (1.2 g, 4.47 mmol)
was dissolved in 1.4 mL of TFA and the resulting solution was
stirred at 0 8C for 1.5 h. Then the solvent was evaporated and the
residue was dissolved in EtOAc and washed with a saturated aque-
ous NaHCO3. The organic phase was dried over anhydrous Na2SO4,
filtered and concentrated affording the title compound (99%
yield). 1H NMR (300 MHz, CDCl3): d=3.87 (s, 3H), 4.43 (br s, 2H),
6.30 (dd, J=8.2, 0.9 Hz, 1H), 6.36 (dd, J=7.5, 1.5 Hz, 1H), 7.16 ppm
(t, J=8.2 Hz, 1H); ESI-MS m/z 169 [M+H]+ .
1-(3-Methoxy-2-nitrophenyl)-1H-pyrrole (11): To a solution of 3-
methoxy-2-nitroaniline 10 (500 mg, 2.97 mmol) in acetic acid
(10.0 mL) and water (2.0 mL), 2,5-dimethoxytetrahydrofuran
(385 mL, 2.97 mmol) in acetic acid (1.0 mL) was added dropwise.
The solution was heated at 100 8C for 15 min. After removal of the
solvent, the dark-brown reaction mixture was diluted with EtOAc
and neutralized with an aqueous saturated solution of Na2CO3.
Then, it was extracted with EtOAc (3V100 mL), dried over anhy-
drous Na2SO4, filtered, and concentrated. Compound 11 (97%
yield) was obtained as a colorless solid. 1H NMR (300 MHz, CDCl3):
d=3.83 (s, 3H), 6.41 (d, J=1.5 Hz, 2H), 6.94 (dd, J=7.5, 1.5 Hz,
1H), 7.26 (d, J=1.5 Hz, 2H), 7.44 (dd, J=7.5, 1.5 Hz, 1H), 7.73 ppm
(t, J=8.2 Hz, 1H); ESI-MS m/z 219 [M+H]+ .
2-Methoxy-6-(1H-pyrrol-1-yl)aniline (12): To a solution of 1-(3-me-
thoxy-2-nitrophenyl)-1H-pyrrole (11) (680 mg, 3.12 mmol) in 75%
EtOH (8.0 mL), CaCl2 (229 mg, 1.56 mmol) and iron powder (1.23 g,
7.09 mmol) were added. The reaction mixture was heated at reflux
for 2 h, then was filtered through a Celite pad. The solvent was re-
moved and the residue was dissolved in CHCl3 and washed with
water. The organic phase was dried over anhydrous Na2SO4, filtered
and concentrated. The compound was submitted to the subse-
quent step without further purification (87% yield). 1H NMR
(300 MHz, CDCl3): d=3.83 (s, 3H), 6.27 (br s, 2H), 6.41 (d, J=1.5 Hz,
2H), 6.70 (t, J=8.2 Hz, 1H), 6.85 (dd, J=7.5, 1.5 Hz, 1H), 6.93 (dd,
J=7.5, 1.5 Hz, 1H), 7.26 ppm (d, J=1.5 Hz, 2H); ESI-MS m/z 189
[M+H]+ .
6-Methoxypyrrolo[1,2-a]quinoxalin-4(5H)-one (13): To a solution
of 12 (1.83 g, 9.73 mmol) in toluene (26.0 mL), triphosgene
(778 mg, 2.63 mmol) was added and the resulting solution was
heated at reflux for 2 h. Then the reaction mixture was cooled
under nitrogen flow and the solvent was evaporated. The residue
was purified by silica gel column chromatography (CHCl3/EtOAc
2:1) affording the title compound (52% yield) as colorless solid.
1H NMR (300 MHz, CDCl3): d=3.97 (s, 3H), 6.67–6.69 (m, 1H), 6.81
(dd, J=8.2, 0.9 Hz, 1H), 7.14 (t, J=8.2 Hz, 1H), 7.25–7.28 (m, 2H),
7.64–7.65 (m, 1H), 8.42 ppm (br s, 1H); ESI-MS m/z 215 [M+H]+ .
6-Hydroxypyrrolo[1,2-a]quinoxalin-4(5H)-one (14): To a suspen-
sion of 6-methoxypyrrolo[1,2-a]quinoxalin-4(5H)-one (13) (100 mg,
0.47 mmol) in dry CH2Cl2 (6.0 mL), boron tribromide (1m solution
in CH2Cl2, 1.87 mL, 1.87 mmol) was added at @78 8C. The reaction
mixture was then allowed to warm to room temperature and
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stirred for 12 h. A saturated aqueous solution of Na2CO3 was added
to quench the reaction. The residue was extracted with EtOAc (3V
20 mL). The combined organic extracts were dried over anhydrous
Na2SO4, filtered, and concentrated. Column chromatography
(CHCl3/EtOAc 1:1) provided the title compound (11% yield) as a
colorless solid. 1H NMR (300 MHz, CD3OD): d=6.68–6.70 (m, 1H),
6.79 (d, J=8.2 Hz, 1H), 7.07 (t, J=8.2 Hz, 1H), 7.18 (d, J=2.9 Hz,
1H), 7.34 (d, J=8.2 Hz, 1H), 7.92 ppm (s, 1H); ESI-MS m/z 199
[M@H]@ .
4-Oxo-4,5-dihydropyrrolo[1,2-a]quinoxalin-6-yl 6-phenylhexyl-
carbamate (5 f): The title compound was prepared according to
the procedure described for 5a starting from 6-hydroxypyrrolo[1,2-
a]quinoxalin-4(5H)-one 14 (10 mg, 0.05 mmol), phenylhexyl isocya-
nate 7b (41 mg, 0.20 mmol) and TEA (28 mL, 0.20 mmol). Column
chromatography (CHCl3) afforded the title compound (30% yield)
as a colorless solid. 1H NMR (300 MHz, CDCl3): d=1.36 (m, 4H), 1.57
(m, 4H), 2.55 (t, J=7.5 Hz, 2H), 3.31 (t, J=5.9 Hz, 2H), 6.70 (d, J=
2.3 Hz, 1H), 7.11–7.26 (m, 7H), 7.46 (d, J=8.5 Hz, 1H), 7.61 (d, J=
8.2 Hz, 1H), 7.70 (s, 1H), 10.95 ppm (s, 1H); 13C NMR (75 MHz,
CDCl3): d=26.9, 29.1, 30.1, 31.5, 36.1, 41.6, 110.3, 112.4, 113.7,
117.8, 118.7, 120.8, 123.0, 124.2, 125.5, 125.8, 128.5 (2), 128.6 (2),
139.7, 142.9, 153.6, 156.7 ppm; ESI-MS m/z 426 [M+Na]+ ; Elemen-
tal analysis calcd (%) for C24H25N3O3 : C 71.44, H 6.25, N 10.41,
found: C 71.76, H 6.09, N 10.27.
N-(5-Hydroxy-2-nitrophenyl)acetamide (16): To a solution of 15
(1.0 g, 6.62 mmol) in acetic anhydride (5.0 mL), a mixture of conc.
HNO3 (3.6 mL) and acetic acid (3.6 mL) was added and the reaction
was stirred at 25 8C for 8 h. HCl (2n, 5.0 mL) was added to quench
the excess of acetic anhydride and the mixture was diluted with
water. The resulting precipitate was filtered and washed with cold
water to afford the pure title compound (98% yield) as a yellow
solid. 1H NMR (300 MHz, CDCl3): d=2.24 (s, 3H), 7.07 (d, J=7.6 Hz,
1H), 7.35 (br s, 1H), 7.46 (s, 1H), 8.07 (d, J=9.4 Hz, 1H), 10.82 ppm
(s, 1H); ESI-MS m/z 195 [M@H]@ .
4-Amino-3-(1H-pyrrol-1-yl)phenol (17): Compound 16 (1.2 g,
6.49 mmol) was dissolved in concentrated HCl (10.0 mL) and the
resulting suspension was stirred at 110 8C for 5 min. The mixture
was cooled to 25 8C, diluted with water and the aqueous phase
was extracted with EtOAc (3V15.0 mL). The combined organic
layers were dried over Na2SO4, filtered, and concentrated to afford
the intermediate 3-amino-4-nitrophenol (95% yield) that was car-
ried on without any further purification. 1H NMR (300 MHz,
[D6]acetone): d=6.24 (dd, J=9.4, 2.6 Hz, 1H), 6.45 (d, J=2.4 Hz,
1H), 7.01 (br s, 2H), 7.97 (d, J=9.4 Hz, 1H), 9.37 ppm (s, 1H); ESI-
MS m/z 153 [M@H]@ .
A stirred solution of 3-amino-4-nitrophenol (950 mg, 6.17 mmol)
and 2,5-dimethoxytetrahydrofuran (960 mL, 7.41 mmol) in 1,4-diox-
ane (20.0 mL), was stirred at 120 8C for 15 min before adding 5n
HCl (1.5 mL). The mixture was stirred at 110 8C for further 5 min,
then cold water was added and the resulting white precipitate was
filtered and washed with cold water to afford the pure 4-nitro-3-
(1H-pyrrol-1-yl)phenol (70% yield) as an amorphous solid. 1H NMR
(300 MHz, CDCl3): d=6.36 (d, J=1.5 Hz, 2H), 6.79 (d, J=1.5 Hz,
2H), 6.85 (s, 1H), 7.17 (d, J=2.6 Hz, 1H), 7.92 ppm (d, J=8.5 Hz);
ESI-MS m/z 203 [M@H]@ .
To a solution of 4-nitro-3-(1H-pyrrol-1-yl)phenol (400 mg, 1.96 mmol)
in EtOAc (10.0 mL) SnCl2·2H2O (2.2 g, 9.8 mmol) was added and the
reaction was stirred at 25 8C for 2 h. A saturated solution of
NaHCO3 was added and the aqueous phase was extracted with
EtOAc (3V20.0 mL). The combined organic layers were dried over
Na2SO4, filtered and evaporated. The crude was purified by means
of chromatography on silica gel (petroleum ether/Et2O 3:2) to give
pure compound 17 (85% yield) as a colorless solid. 1H NMR
(300 MHz, CDCl3): d=4.09 (br s, 2H), 6.33 (s, 2H), 6.62–6.67 (m, 3H),
7.80 (s, 2H), 7.16 ppm (s, 1H); ESI-MS m/z 175 [M+H]+ .
8-Hydroxypyrrolo[1,2-a]quinoxalin-4(5H)-one (18): Starting from
17 (100 mg, 0.57 mmol), the title compound was obtained follow-
ing the same procedure reported for 13. The crude was purified by
means of chromatography on silica gel (MeOH/CHCl3 1:20) to pro-
vide title compound (36% yield) as a colorless solid. 1H NMR
(300 MHz, [D6]DMSO): d=6.63 (m, 1H), 6.73–6.76 (m, 1H), 6.70 (m,
1H), 7.09–7.12 (m, 1H), 7.36 (s, 1H), 8.01 (m 1H), 9.57 (s, 1H),
11.00 ppm (s, 1H); ESI-MS m/z 199 [M@H]@ .
4-Oxo-4,5-dihydropyrrolo[1,2-a]quinoxalin-8-yl 6-phenylhexyl-
carbamate (5g): Starting from 18 (40 mg, 0.20 mmol) and 6-phe-
nylhexyl isocyanate (165 mg, 0.80 mmol), the title compound was
obtained following the same procedure reported for 5a. The crude
was purified by means of chromatography on silica gel (Et2O/CHCl3
2:1) to afford title compound (10% yield) as a colorless solid.
1H NMR (300 MHz, CD3OD): d=1.39–1.42 (m, 4H), 1.55–1.67 (m,
4H), 2.58 (t, J=7.5 Hz, 2H), 3.18 (t, J=7.0 Hz, 2H), 6.69–6.71 (m,
1H), 7.05 (dd, J=8.8, 2.4 Hz, 1H), 7.13–7.30 (m, 7H), 7.73 (d, J=
2.4 Hz, 1H), 7.94–7.96 ppm (m, 1H); 13C NMR (75 MHz, CD3OD): d=
26.5, 28.8, 29.5, 31.5, 35.7, 40.9, 108.6, 112.3, 113.2, 117.2, 118.2,
119.4, 123.0, 123.7, 125.5 (2C), 128.1 (2C), 128.2 (2C), 142.7, 147.3,
155.9, 156.7 ppm; ESI-MS m/z 426 [M+Na]+ ; Elemental analysis
calcd (%) for C24H25N3O3 : C 71.44, H 6.25, N 10.41, found: C 71.37,
H 6.51, N 10.58.
Methyl 4-methoxy-2-(1H-pyrrol-1-yl)benzoate (20): To an ice-
cooled solution of 19 (1.0 g, 5.07 mmol) in MeOH (10.0 mL), SOCl2
(740 mL, 10.15 mmol) was added dropwise and the reaction mix-
ture was stirred at 25 8C for 10 h. Solvent was removed under re-
duced pressure and the residue was taken up with EtOAc and
washed with a saturated solution of NaHCO3. The organic phase
was dried over Na2SO4, filtered and evaporated to obtain methyl 4-
methoxy-2-nitrobenzoate (quantitative yield) which was carried on
without any further purification. 1H NMR (300 MHz, CDCl3): d=3.84
(s, 3H), 3.99 (s, 3H), 7.31 (dd, J=8.8, 2.6 Hz, 1H), 7.42 (d, J=2.6 Hz,
1H), 7.88 ppm (d, J=8.8 Hz, 1H); ESI-MS m/z 212 [M+H]+ .
To a solution of methyl 4-methoxy-2-nitrobenzoate (5.07 mmol) in
EtOAc (10.0 mL) SnCl2·2H2O (3.57 g, 15.84 mmol) was added and
the reaction was stirred at 25 8C for 2 h. The reaction was
quenched with a saturated solution of NaHCO3 and the aqueous
phase was extracted with EtOAc (3V25.0 mL). The combined or-
ganic layers were dried over Na2SO4, filtered and evaporated to
afford methyl 2-amino-4-methoxybenzoate (quantitative yield) as a
pale-yellow solid which was used in the next step without any fur-
ther purification. 1H NMR (300 MHz, CDCl3): d=3.78 (s, 3H), 3.83 (s,
3H), 5.52 (br s, 2H), 6.11 (d, J=2.4 Hz, 1H), 6.23 (dd, J=9.1, 2.4 Hz,
1H), 7.78 ppm (d, J=9.1, 1H); ESI-MS m/z 182 [M+H]+ , 204 [M+
Na]+ .
Starting from methyl 2-amino-4-methoxybenzoate (300 mg,
1.70 mmol), the title compound was obtained following the same
procedure reported for 17. The crude was purified by means of
chromatography on silica gel (petroleum ether/CHCl3 1:1) to afford
pure compound 20 (87% yield) as a withe solid. 1H NMR (300 MHz,
CDCl3): d=3.70 (s, 3H), 3.83 (s, 3H), 6.32 (t, J=2.2 Hz, 2H), 6.82 (t,
J=2.2 Hz, 2H), 6.87–6.91 (m, 2H), 7.84 ppm (d, J=8.3 Hz, 1H); ESI-
MS m/z 254 [M+Na]+ .
Methyl 2-(2-cyano-1H-pyrrol-1-yl)-4-methoxybenzoate (21): To an
ice-cooled solution of dry DMF (1.0 mL) and dry 1,2-DCE (2.0 mL),
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(COCl)2 (135 mL, 1.55 mmol) was added. The mixture was allowed
to warm to 25 8C and stirred for 15 min. Then it was cooled to 0 8C
and a solution of 20 (325 mg, 1.41 mmol) in dry 1,2-DCE (1.0 mL)
was added. The reaction was stirred at 25 8C for further 15 min. A
solution of NH2OH·HCl (108 mg, 1.55 mmol) and pyridine (125 mL,
1.55 mmol) in dry DMF (1.0 mL) was added and the mixture was
stirred at 120 8C for 10 h. A saturated solution of NaHCO3 was
added dropwise and the aqueous phase was extracted with EtOAc
(3V10.0 mL). The combined organic layers were dried over anhy-
drous Na2SO4, filtered, and evaporated. The crude was purified by
means of chromatography on silica gel (petroleum ether/Et2O 1:1)
to afford title compound (47% yield) as a colorless solid. 1H NMR
(300 MHz, CDCl3): d=3.72 (s, 3H), 3.90 (s, 3H), 6.33–6.35 (m, 1H),
6.89 (d, J=2.6 Hz, 1H), 6.92–6.94 (m, 1H), 6.97 (dd, J=4.0, 1.6 Hz,
1H), 7.03 (dd, J=8.8, 2.3 Hz, 1H), 8.06 ppm (d, J=8.8 Hz, 1H); ESI-
MS m/z 279 [M+Na]+ .
9-Methoxy-4H-benzo[f]pyrrolo[1,2-a][1,4]diazepin-6(5H)-one
(22): To a stirred suspension of 21 (290 mg, 1.13 mmol) and CoCl2
(294 mg, 2.26 mmol) in MeOH (10.0 mL), NaBH4 (420 mg,
11.30 mmol) was added and reaction was stirred at 25 8C for
20 min. HCl (2n) was added and solvent was removed under re-
duced pressure. The solution was basified with 2n NaOH and the
aqueous phase was extracted with EtOAc (3V10.0 mL). The com-
bined organic layers were dried over Na2SO4, filtered, and evapo-
rated. The crude was purified by means of chromatography on
silica gel (EtOAc) to afford title compound (64% yield) as a color-
less solid. 1H NMR (300 MHz, CDCl3): d=3.90 (s, 3H), 4.20 (brd, 2H),
6.12 (s, 1H), 6.28 (s, 1H), 6.87–6.92 (m, 2H), 7.03 (s, 1H), 7.32 (br s,
1H), 7.97 ppm (d, J=8.8 Hz, 1H); ESI-MS m/z 229 [M+H]+ , 251
[M+Na]+ .
6-Oxo-5,6-dihydro-4H-benzo[f]pyrrolo[1,2-a][1,4]diazepin-9-yl-6-
phenylhexylcarbamate (5h): Starting from 22, hydroxy-4H-ben-
zo[f]pyrrolo[1,2-a][1,4]diazepin-6(5H)-one was obtained following
the same procedure reported for 14. The crude was purified by
means of chromatography on silica gel (CHCl3/EtOAc 1:1) to afford
compound hydroxy-4H-benzo[f]pyrrolo[1,2-a][1,4]diazepin-6(5H)-one
(50% yield) as a colorless solid. 1H NMR (300 MHz, [D6]acetone): d=
4.22 (s, 2H), 6.11 (d, J=2.3 Hz, 1H), 6.20–6.24 (m, 1H), 6.85–6.93
(m, 2H), 7.10–7.12 (m, 1H), 7.81–7.86 (m, 2H), 9.42 ppm (br s, 1H);
ESI-MS m/z 213 [M@H]@ .
Starting from hydroxy-4H-benzo[f]pyrrolo[1,2-a][1,4]diazepin-6(5H)-
one (14 mg, 0.06 mmol) and 6-phenylhexyl isocyanate 7b (50 mg,
0.25 mmol), the title compound was obtained following the same
procedure reported for 5a. The crude was purified by means of
chromatography on silica gel (MeOH/CH2Cl2 1:20) to afford title
compound 5h (60% yield) as a colorless solid. 1H NMR (300 MHz,
CDCl3): d=1.38–1.41 (m, 4H), 1.57–1.70 (m, 4H), 2.62 (t, J=7.6 Hz,
2H), 3.27 (q, J=6.1 Hz, 2H), 4.21 (s, 2H), 5.14 (br s, 1H), 6.11 (brd,
1H), 6.27 (t, J=2.9 Hz, 1H), 7.01 (brd, 1H), 7.12–7.31 (m, 7H),
7.96 ppm (d, J=8.5 Hz, 1H); 13C NMR (75 MHz, CDCl3): d=26.8,
29.1, 29.9, 31.6, 36.1, 37.7, 41.6, 107.3, 110.8, 115.7, 119.3, 120.9,
125.9, 128.5 (2C), 128.6 (2C), 132.2, 133.6, 138.6, 142.8, 153.7, 154.6,
169.6 ppm; ESI-MS m/z 418 [M+H]+ ; Elemental analysis calcd (%)
for C25H27N3O3 : C 71,92, H 6,52, N 10,06, found: C 72.18, H 6.27, N
10.34.
Methyl 1-(2-cyano-5-methoxyphenyl)-1H-pyrrole-2-carboxylate
(24): To a stirred solution of methyl 1H-pyrrole-2-carboxylate (1.0 g,
8.00 mmol) in dry DMF (25.0 mL), Cs2CO3 (13.0 g, 40.00 mmol) and
23 (1.5 g, 9.60 mmol) were added and the reaction was stirred at
50 8C under N2 atmosphere for 12 h. Solvent was removed under
reduced pressure and the crude was taken up with a saturated so-
lution of NH4Cl. The aqueous phase was extracted with CH2Cl2 (3V
25.0 mL) and the combined organic layers were dried over Na2SO4,
filtered, and evaporated. The crude was purified by means of chro-
matography on silica gel (EtOAc/petroleum ether 1:6) to afford
compound title compound (30% yield) as a colorless solid. 1H NMR
(300 MHz, CDCl3): d=3.74 (s, 3H), 3.87 (s, 3H), 6.37 (dd, J=3.8,
2.9 Hz, 1H), 6.90 (d, J=2.5 Hz, 1H), 6.94 (q, J=2.6 Hz, 1H), 7.00
(dd, J=8.7, 2.5 Hz, 1H), 7.13 (dd, J=3.9, 1.7 Hz, 1H), 7.64 ppm (d,
J=8.7 Hz, 1H); ESI-MS m/z 257 [M+H]+ , 279 [M+Na]+ .
9-Hydroxy-5,6-dihydro-4H-benzo[f]pyrrolo[1,2-a][1,4]diazepin-4-
one (25): Starting from 24 (600 mg, 2.34 mmol), 9-methoxy-5,6-di-
hydro-4H-benzo[f]pyrrolo[1,2-a][1,4]diazepin-4-one was obtained fol-
lowing the same procedure reported for 22. The crude was puri-
fied by means of chromatography on silica gel (EtOAc/petroleum
ether 1:1) to afford compound 9-methoxy-5,6-dihydro-4H-benzo[f]-
pyrrolo[1,2-a][1,4]diazepin-4-one (71% yield) as a colorless solid.
1H NMR (300 MHz, CDCl3): d=3.80 (s, 3H), 4.14 (s, 2H), 6.36–6.47
(m, 1H), 6.75 (dd, J=8.3, 1.9 Hz, 1H), 6.83 (d, J=2.3 Hz, 1H), 7.07–
7.15 (m, 1H), 7.15–7.24 (m, 2H), 8.23 ppm (br s, 1H); ESI-MS m/z
229 [M+H]+ , 251 [M+Na]+ .
Starting from 9-methoxy-5,6-dihydro-4H-benzo[f]pyrrolo[1,2-a][1,4]di-
azepin-4-one (380 mg, 1.66 mmol), the title compound was ob-
tained following the same procedure reported for 14. The crude
was purified by means of chromatography on silica gel (EtOAc) to
afford title compound (50% yield) as a colorless solid. 1H NMR
(300 MHz, CD3OD): d=4.08 (s, 2H), 6.42 (t, J=3.1 Hz, 1H), 6.74 (dd,
J=8.2, 2.1 Hz, 1H), 6.85 (d, J=2.2 Hz, 1H), 7.02 (dd, J=3.8, 1.1 Hz,
1H), 7.21 (d, J=8.2 Hz, 1H), 7.32–7.40 ppm (m, 1H); ESI-MS m/z
215 [M+H]+ , 237 [M+Na]+ .
4-Oxo-5,6-dihydro-4H-benzo[f]pyrrolo[1,2-a][1,4]diazepin-9-yl-(6-
phenylhexyl)carbamate (5 i): Starting from 25 (10 mg, 0.05 mmol)
and 6-phenylhexyl isocyanate 7b (13 mg, 0.06 mmol), the title
compound was obtained following the same procedure reported
for 5a. The crude was purified by means of chromatography on
silica gel (MeOH/CH2Cl2 1:20) to afford the title compound (52%
yield) as a colorless solid. 1H NMR (300 MHz, CDCl3): d=1.33–1.44
(m, 4H), 1.48–1.71 (m, 4H), 2.61 (t, J=5.1 Hz, 2H), 3.24 (q, J=
6.6 Hz, 2H), 4.17 (brd, 2H), 5.25 (t, J=4.2 Hz, 1H), 6.42 (t, J=
3.3 Hz, 1H), 7.01 (dd, J=8.2, 2.1 Hz, 1H), 7.07–7.22 (m, 6H), 7.22–
7.33 (m, 3H), 7.45 ppm (t, J=5.2 Hz, 1H); ESI-MS m/z 375 [M+H]+ ;
HRMS (ESI) m/z calcd for C25H28N3O3
+ : 418.2125, found 418.2117
[M+H]+ ; calcd for: C25H27N3NaO3
+ : 440.1945, found 440.1936 [M+
Na]+ , calcd for C50H55N6O6
+ : 835.4178, found 835.4168 [2M+H]+ ;
Elemental analysis calcd (%) for C25H27N3O3 : C 71.92, H 6.52, N
10.06, found C 72.11, H 6.35, N 10.20.
4-Oxo-5,6-dihydro-4H-benzo[f]pyrrolo[1,2-a][1,4]diazepin-9-yl-(2-
(2-phenoxyethoxy)ethyl) carbamate (5 j): Starting from 25 (10 mg,
0.05 mmol) and isocyanate 26a (13 mg, 0.06 mmol), the title com-
pound was obtained following the same procedure reported for
5a. The crude was purified by means of chromatography on silica
gel (MeOH/CH2Cl2 1:20) to afford title compound (55% yield) as a
colorless solid. 1H NMR (300 MHz, CDCl3): d=3.46–3.54 (m, 2H),
3.71 (t, J=4.8 Hz, 2H), 3.80–3.92 (m, 2H), 4.07–4.25 (m, 4H), 5.66 (t,
J=4.5 Hz, 1H), 6.43 (t, J=3.3 Hz, 1H), 6.89–6.99 (m, 3H), 7.00–7.17
(m, 4H), 7.20 (s, 1H), 7.23–7.34 ppm (m, 3H); 13C NMR (75 MHz,
CDCl3): d=41.3, 43.2, 67.5, 69.9, 70.1, 111.2, 114.8, 116.8, 118.7,
119.9, 121.4, 125.1, 128.7, 129.0, 129.3, 129.8, 140.0, 151.7, 154.4,
158.8 ppm; ESI-MS m/z 422 [M+H]+ (100); Elemental analysis
calcd (%) for C23H23N3O5 : C 65.55, H 5.50, N 9.97, found: C 65.23, H
5.29, N 9.76.
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4-Oxo-5,6-dihydro-4H-benzo[f]pyrrolo[1,2-a][1,4]diazepin-9-yl-(2-
(2-(2-fluorophenoxy)ethoxy)ethyl) carbamate (5k): Starting from
25 (10 mg, 0.05 mmol) and isocyanate 26b (14 mg, 0.06 mmol),
the title compound was obtained following the same procedure
reported for 5a. The crude was purified by means of chromatogra-
phy on silica gel (MeOH/CH2Cl2 1:20) to afford title compound
(47% yield) as a colorless solid. 1H NMR (300 MHz, CDCl3): d=3.49
(q, J=10.3 Hz, 2H), 3.71 (t, J=5.0 Hz, 2H), 3.84–3.93 (m, 2H), 4.14–
4.26 (m, 4H), 5.65 (t, J=5.6 Hz, 1H), 6.42 (dd, J=3.8, 2.9 Hz, 1H),
6.86–6.96 (m, 1H), 6.96–7.11 (m, 4H), 7.11–7.17 (m, 3H), 7.17–7.23
(m, 1H), 7.28 ppm (s, 1H); 13C NMR (75 MHz, CDCl3): d=41.3, 43.2,
69.3, 69.7, 70.2, 111.3, 115.8, 116.60 (d, JC-F=18.2 Hz), 116.9, 118.9,
120.0, 121.98 (d, JC-F=6.8 Hz), 124.57 (d, JC-F=3.9 Hz), 125.3, 128.8,
129.3, 140.0, 146.93 (d, JC-F=10.6 Hz), 151.7, 153.13 (d, JC-F=
245.6 Hz), 154.4, 164.2 ppm; ESI-MS m/z 440 [M+H]+ ; Elemental
analysis calcd (%) for C23H22FN3O5 : C 62.86, H 5.05, N 9.56, found: C
63.12, H 5.18, N 9.47.
4-Oxo-5,6-dihydro-4H-benzo[f]pyrrolo[1,2-a][1,4]diazepin-9-yl-(2-
(2-(4-fluorophenoxy)ethoxy)ethyl) carbamate (5 l): Starting from
25 (10 mg, 0.05 mmol) and isocyanate 26c (14 mg, 0.06 mmol), the
title compound was obtained following the same procedure re-
ported for 5a. The crude was purified by means of chromatogra-
phy on silica gel (MeOH/CH2Cl2 1:20) to afford title compound
(43% yield) as a colorless solid. 1H NMR (300 MHz, CDCl3): d=3.50
(q, J=5.2 Hz, 2H), 3.70 (t, J=5.0 Hz, 2H), 3.82–3.89 (m, 2H), 4.07–
4.14 (m, 2H), 4.20 (brd, J=3.4 Hz, 2H), 5.61 (t, J=5.7 Hz, 1H), 6.43
(t, J=3.8 Hz, 1H), 6.81–6.92 (m, 2H), 6.92–7.11 (m, 4H), 7.11–7.17
(m, 2H), 7.17–7.22 (m, 1H), 7.26–7.31 ppm (m, 1H); 13C NMR
(75 MHz, CDCl3): d=41.3, 43.1, 68.2, 69.9, 70.1, 111.3, 115.9 (d, JC-F=
8.0 Hz), 116.1 (d, JC-F=23.1 Hz), 116.8, 118.8, 119.9, 125.2, 128.6,
128.9, 129.2, 140.0, 151.6, 154.3, 155.0 (d, JC-F=2.1 Hz), 157.6 (d, JC-
F=238.7 Hz), 164.2 ppm; ESI-MS m/z 440 [M+H]
+ ; Elemental anal-
ysis calcd (%) for C23H22FN3O5 : C 62.86, H 5.05, N 9.56, found: C
62.67, H 4.78, N 9.21.
Molecular docking studies
a) Ligand preparation : Three-dimensional structures of all com-
pounds in this study were built by means of Maestro (Maestro, ver-
sion 9.3, Schrçdinger LLC, New York, NY, 2012). Molecular energy
minimizations were performed by means of MacroModel (Macro-
Model version 9.9, Schrçdinger LLC, New York, NY, 2012) using the
Optimized Potentials for Liquid Simulations-all atom (OPLS-AA)
force field 2005.[41] The solvent effects were simulated using the an-
alytical Generalized-Born/Surface Area (GB/SA) model,[42] and no
cutoff for nonbonded interactions was selected. Polak–Ribiere con-
jugate gradient (PRCG) method with 1000 maximum iterations and
0.001 gradient convergence threshold was employed. All com-
pounds reported in this paper were treated by LigPrep application
(LigPrep version 2.5, Schrçdinger LLC, New York, NY, 2012), imple-
mented in Maestro suite 2011, generating the most probable ioni-
zation state of any possible enantiomers and tautomers at cellular
pH value (7:0.5) and also for avoiding potential error in the struc-
tures.
b) Protein preparation : The three-dimensional structure of FAAH
(PDB ID: 3PPM[43]) was taken from the PDB and imported into
Schrçdinger Maestro molecular modeling environment. Water mol-
ecules and compounds used for the crystallization were removed
from the available experimental structure. The obtained enzyme
was submitted to protein preparation wizard implemented in
Maestro suite 2012. This protocol through a series of computation-
al steps, allowed us to obtain a reasonable starting structure of the
protein for molecular docking calculations by a series of computa-
tional steps. In particular, we performed three steps to: 1) add hy-
drogen atoms, 2) optimize the orientation of hydroxy groups, Asn,
and Gln, and the protonation state of His, and 3) perform a con-
strained refinement with the impref utility, setting the max RMSD
of 0.30. The impref utility consists of a cycles of energy minimiza-
tion based on the impact molecular mechanics engine and on the
OPLS_2005 force field.[41]
c) Molecular docking : Molecular docking was carried out using
the Schrçdinger suite 2012 by applying the IFD protocol (Schrç-
dinger Suite 2012 Induced Fit Docking protocol; Glide version 5.8,
Schrçdinger LLC, New York, NY, 2012; Prime version 3.1, Schrçding-
er LLC, New York, NY, 2012). This procedure induces conformational
changes in the binding site to accommodate the ligand and ex-
haustively identify possible binding modes and associated confor-
mational changes by side-chain sampling and backbone minimiza-
tion. The protein and the ligands used were prepared as reported
in the previous paragraphs. The boxes for docking calculation were
built taking into account the centroid of the co-crystallized ligand
for FAAH enzyme. Complexes within 30.0 kcalmol@1 of minimum
energy structure were taken forward for redocking. The Glide re-
docking stage was performed by XP (Extra Precision) methods. The
calculations were performed using default IFD protocol parame-
ters. No hydrogen bonding or other constraints were used. The
choice of IFD coupled to XP was done after the assessment of two
docking protocols (IFD-SP and IFD-XP). From the computational
outputs we observed that IFD-XP was able to correctly accommo-
date the co-crystallized ligands, belonging to the FAAH crystal
structures 3PPM, 3QJ9 and 2VYA, with lower RMSD than IFD-SP
(data not shown).
Enzymatic assays
FAAH and MAGL activities were detected in cells as previously de-
scribed.[44–45] In particular, AEA hydrolysis was measured by incubat-
ing samples with the 10000Vg membrane fraction of rat brain
(70 mg per sample) and synthetic N-arachidonoyl-[14C]ethanolamine
(110mCimmol@1, ARC, St. Louis, MO, USA) properly diluted with
AEA (Tocris Bioscience, Avonmouth, Bristol, UK) in Tris·HCl 50 mm,
at pH 9.00–10.00 at 37 8C for 30 min. After incubation, the amount
of [14C]ethanolamine produced was measured by scintillation
counting of the aqueous phase after extraction of the incubation
mixture with two volumes of CHCl3/MeOH 1:1 (v/v). 2-AG hydrolysis
was measured by incubating the 10000Vg cytosolic fraction of
COS-7 cells (100 mg per sample), which contains high levels of
MAGL, and synthetic 2-arachidonoyl-[3H]glycerol (40 Cimmol@1,
ARC, St. Louis, MO, USA) properly diluted with 2-AG (Cayman
Chemicals, Ann Arbor, MI, USA) in Tris·HCl 50 mm, at pH 7.0 at
37 8C for 20 min. After incubation, the amount of [3H]glycerol pro-
duced was measured by scintillation counting of the aqueous
phase after extraction of the incubation mixture with two volumes
of CHCl3/MeOH 1:1 (v/v). All data are expressed as means :SD of
three separate experiments of the concentration exerting 50% in-
hibition of [14C]AEA hydrolysis (IC50) calculated by fitting sigmoidal
concentration-response curves by GraphPad Prism software.
Competition binding assay
Membranes from HEK-293 cells overexpressing the respective
human recombinant CB1 receptor (Bmax=2.5 pmolmg
@1 protein)
and human recombinant CB2 receptor (Bmax=4.7 pmolmg
@1 pro-
tein) were incubated with [3H]CP-55,940 (0.14 nm, Kd=0.18 nm ;
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and 0.084 nm, Kd=0.31 nm, respectively, for CB1 and CB2 receptors)
as the high-affinity ligand. Competition curves were performed as
previously reported[46] by displacing [3H]CP-55,940 with increasing
concentration of compounds (0.1–50 mm). Nonspecific binding was
defined by 10 mm of WIN55,212-2 as the heterologous competitor
(Ki values 9.2 and 2.1 nm, respectively, for CB1 and CB2 receptors).
IC50 values were determined for compounds showing >50% dis-
placement at 10 mm. All compounds were tested following the pro-
cedure described by the manufacturer (PerkinElmer, Italy). Displace-
ment curves were generated by incubating drugs with [3H]CP-
55,940 for 90 min at 30 8C. Ki values were calculated by applying
the Cheng–Prusoff equation to the IC50 values (obtained by Graph-
Pad Prism) for the displacement of the bound radioligand by in-
creasing concentrations of the test compound. Data represent
mean values of three separate experiments performed in duplicate
and are expressed as the average of Ki :SD.
Cellular in vitro study
a) Cell culture and treatments : IMR32 cells line (obtained from
American Type Culture Collection, ATCC), were cultured in EMEM
supplemented with 10% fetal bovine serum (Lonza, Milan, Italy),
1% of l-glutammine (Lonza, Milan, Italy) and 1% of penicillin/
streptomycin antibiotics (Lonza, Milan, Italy) at 37 8C in 5% CO2.
The different formulations (compounds 3, 5h, and 5 i) were dis-
solved in DMSO as stock solutions at a final concentration of
10 mm. Stock solutions were then diluted with cell culture
medium, EMEM with Earle’s Balanced Salt Solution, to obtain an in-
termediate dose solution (100 mm), to be used for the used dilu-
tions (50, 10, 5, 1, 0.5, and 0.1 mm). Control vehicle was represented
by DMSO ranging from 0.5% to 0.001%.
b) Cytotoxicity determination : IMR32 cells were seeded 100000
cells per well in 96-well plate and were grown to confluence, then
were treated with the tested substances in EMEM supplemented
with 10% FBS. The effects of tested compounds on cellular mor-
phology were checked after 24 h using a built-in camera in an in-
verted Nikon Eclipse microscope (20V magnification). Cytotoxicity
was determined by LDH release in the media, measured by enzy-
matic assay: in the first step NAD+ is reduced to NADH/H+ by
LDH-catalyzed conversion of lactate into pyruvate; in the second
step the catalyst (diaphorase) transfers H/H+ from NADH/H+ to
tetrazolium salt which is reduced to formazan. For total release of
intracellular LDH (positive control of 100% cell death), a triplicate
set of IMR32 cells were treated with 1% Triton X-100 for 30 min at
37 8C, according to the manufacturer’s protocol (Roche, Mannheim,
Germany). The amount of LDH in the supernatant was determined
and calculated according to kit instructions. The amount of LDH re-
lease in each sample was determined by measuring the absorb-
ance at 490 nm using a microplate spectrophotometer. All tests
were performed at least in triplicate. The absorbance measured
from three wells was averaged, and the percentage of LDH re-
leased was calculated as arbitrary units of change relative to 1%
Triton X-100 treated cells.
c) Extraction of nuclear proteins : For nuclear extracts, IMR32 cells
were seeded in a 100 mm petri dish (3V106 cells). After treatments
with various compounds, cells were detached, washed with ice-
cold 1V PBS, and cell pellets were resuspended in hypotonic buffer
containing 10 mm HEPES (pH 7.9), 10 mm KCl, 1.5 mm MgCl2, 0.3%
Nonidet P-40, 0.5 mm dithithreitiol, 0.5 mm phenylmethylsulfonyl
fluoride and protease and phosphatase inhibitor cocktails. The ly-
sates were incubated for 15 min on ice with intermitted mixing
and then centrifuged at 24500Vg for 15 min at 4 8C. The superna-
tant containing the cytosolic proteins was removed and pellet con-
taining the nuclei were resuspended in extraction buffer contain-
ing 20 mm HEPES (pH 7.9), 0.6 m KCl, 1.5 mm MgCl2, 20% glycerol,
0.5 mm phenylmethylsulfonyl fluoride and protease and phospha-
tase inhibitor cocktails and then incubated for 30 min on ice with
intermitted mixing. Samples were centrifuged at 21100Vg for
15 min to obtain supernatants containing nuclear fractions. Protein
concentration was determined by Bradford analysis (Bio-Rad pro-
tein assay; Bio-Rad, Milan, Italy).
d) Western blot analysis : After protein quantification, 60 mg
boiled proteins were separated by 10% SDS-PAGE. Gels were elec-
tro-blotted onto nitrocellulose membranes and then blocked for
90 min in Tris-buffered saline, pH 7.5, containing 0.5% Tween 20
and 5% (w/v) skim milk powder. Membranes were incubated over-
night at 4 8C with the appropriate primary antibody: anti-NF-kB,
p65 subunit, diluted 1:1000 (Millipore, Billerica, MA, USA). The
membranes were finally incubated with the peroxidase-conjugated
secondary anti-rabbit antibody (1:5000) for 1 h. The bound anti-
bodies were detected by chemiluminescence (Bio-Rad, Milan, Italy).
b-Actin was used as loading control. Images of the bands were
digitized using an Epson Stylus SX405 scanner, and the densitome-
try analysis was performed using ImageJ software.
e) Statistical analysis : For each of the variables tested, two-way
analysis of variance (ANOVA) was used. A significant result was in-
dicated by P <0.05. All the results are expressed as mean :SD of
triplicate determinations obtained in three independent experi-
ments. Data were analyzed using the software GraphPad Prism 4.0
(GraphPad Software, Inc. , La Jolla, CA, USA).
Pharmacological in vivo study
a) Animals : Male CD-1 albino mice (Envigo, Varese, Italy) weighing
approximately 22–25 g at the beginning of the experimental pro-
cedure were used. Animals were housed in CeSAL (Centro Stabula-
zione Animali da Laboratorio, University of Florence) and used at
least one week after their arrival. Ten mice were housed per cage
(size 26V41 cm); animals were fed a standard laboratory diet and
tap water ad libitum, and kept at 23:1 8C with a 12 h light/dark
cycle, light at 7:00. All animal manipulations were carried out ac-
cording to the Directive 2010/63/EU of the European parliament
and of the European Union council (22.September, 2010) on the
protection of animals used for scientific purposes. The ethical
policy of the University of Florence complies with the Guide for
the Care and Use of Laboratory Animals of the US National Insti-
tutes of Health (NIH Publication No. 85-23, revised 1996; University
of Florence assurance number: A5278-01). Formal approval to con-
duct the experiments described was obtained from the Animal
Subjects Review Board of the University of Florence. Experiments
involving animals have been reported according to ARRIVE guide-
lines. All efforts were made to minimize animal suffering and to
minimize the number of animals used.
b) Oxaliplatin-induced neuropathic pain model and compound
administration : Oxaliplatin (2.4 mgkg@1) was dissolved in 5% glu-
cose solution and administered i.p. for five consecutive days every
week for two weeks.[40] On day 14, compounds 3, 5h, and 5 i were
administered p.o.[47–48] using 1% carboxymethylcellulose (CMC) as
vehicle.
c) Cold plate test : The animals were placed in a stainless steel box
(12 cmV20 cmV10 cm) with a cold plate as floor. The temperature
of the cold plate was kept constant at 4:1 8C. Pain-related behav-
ior (licking of the hind paw) was observed, and the time (s) of the
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first sign was recorded. The cutoff time of the latency of paw lifting
or licking was set at 60 s.[49] Measurements were performed before
and 15, 30, 45, and 60 min after compound administration.
d) Statistical analysis : Behavioral measurements were performed
on 12 mice for each treatment carried out in two different experi-
mental sets. Results are expressed as mean :SEM. The analysis of
variance of behavioral data was performed by one-way ANOVA,
and Bonferroni’s significant difference procedure was used as post-
hoc comparison. P values less than 0.05 or 0.01 were considered
significant. Investigators were blind to all experimental procedures.
Data were analyzed using the Origin 9 software package (Origin-
Lab, Northampton, USA).
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